{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T12:00:20Z","timestamp":1775736020028,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.beha.2016.10.011","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T05:04:21Z","timestamp":1476939861000},"page":"359-364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["The role of second transplants for leukemia"],"prefix":"10.1016","volume":"29","author":[{"given":"Daniel","family":"Weisdorf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.10.011_bib1","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","article-title":"Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study","volume":"21","author":"Bejanyan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib2","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/bmt.2014.116","article-title":"Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation","volume":"49","author":"Bejanyan","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib3","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","article-title":"Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation","volume":"119","author":"Schmid","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.011_bib4","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.10.011_bib5","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/bmt.2009.300","article-title":"Management of relapse after allo-SCT for AML and the role of second transplantation","volume":"44","author":"Savani","year":"2009","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"19","author":"Thanarajasingam","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1200\/JCO.1989.7.1.50","article-title":"Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy","volume":"7","author":"Mortimer","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.011_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.bbmt.2010.08.001","article-title":"NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on treatment of relapse after allogeneic hematopoietic stem cell transplantation","volume":"16","author":"Porter","year":"2010","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bbmt.2014.10.006","article-title":"Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes","volume":"21","author":"Duncan","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.20.2.405","article-title":"Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation","volume":"20","author":"Levine","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.011_bib12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0145-2126(00)00142-9","article-title":"Combination chemotherapy of intermediate-dose cytarabine, idarubicin, plus etoposide and subsequent mobilized donor leukocyte infusion for relapsed acute leukemia after allogeneic bone marrow transplantation","volume":"25","author":"Lee","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.10.011_bib13","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.bbmt.2011.11.030","article-title":"Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation","volume":"18","author":"Warlick","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib14","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1200\/JCO.2007.11.6053","volume":"25","author":"Schmid","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.011_bib15","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/sj.leu.2403523","article-title":"Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse","volume":"18","author":"Choi","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.011_bib16","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.bbmt.2006.09.005","article-title":"Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience","volume":"13","author":"Arellano","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bbmt.2010.12.713","article-title":"National Cancer Institute's first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: summary and recommendations from the organizing committee","volume":"17","author":"Bishop","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.bbmt.2009.01.009","article-title":"A\u00a0retrospective review of the outcome after second or subsequent allogeneic transplantation","volume":"15","author":"Kedmi","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib19","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib20","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1200\/JCO.2012.44.7961","article-title":"Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change","volume":"31","author":"Christopeit","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.011_bib21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bmt.2008.255","article-title":"Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant","volume":"42","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib22","first-page":"39","article-title":"Outcome of second bone marrow transplantation following a uniform conditioning regimen as therapy for malignant relapse","volume":"17","author":"Chiang","year":"1996","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib23","first-page":"589","article-title":"Second bone marrow transplantation for leukemia in untreated relapse","volume":"14","author":"Martino","year":"1994","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/bmt.2015.285","article-title":"When is second allogeneic HSCT for relapse of acute leukaemia an option?","volume":"51","author":"Christopeit","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib25","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bmt.2015.221","article-title":"Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes","volume":"51","author":"Vrhovac","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2011.06.010","article-title":"EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure","volume":"18","author":"Rezvani","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib27","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0b013e3283257a87","article-title":"Second hematopoietic stem cell transplantation in myeloid malignancies","volume":"16","author":"Arfons","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.beha.2016.10.011_bib29","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.bbmt.2013.04.022","article-title":"Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research","volume":"19","author":"Foran","year":"2013","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib30","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/bmt.2015.193","article-title":"Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years","volume":"50","author":"Andreola","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib31","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1634\/theoncologist.2013-0406","article-title":"Costs of allogeneic hematopoietic cell transplantation using reduced intensity conditioning regimens","volume":"19","author":"Khera","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.beha.2016.10.011_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bmt.1702726","article-title":"Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease","volume":"27","author":"de Lima","year":"2001","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.011_bib33","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1002\/cncr.25500","article-title":"Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study","volume":"116","author":"de Lima","year":"2010","journal-title":"Cancer"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T11:25:46Z","timestamp":1536319546000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S1521692616300640"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.011","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of second transplants for leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}